Results
Awaiting price reaction for this filing.
Uniworth International reported nil revenue from operations for the third consecutive quarter on both standalone and consolidated basis, indicating the company has not generated any business income. Standalone loss for Q3 FY26 stood at Rs. 39.45 lakhs, similar to Rs. 39.21 lakhs in Q3 FY25, taking the nine-month loss to Rs. 117.72 lakhs versus Rs. 117.23 lakhs last year. The consolidated nine-month loss was Rs. 39.46 lakhs, compared to a profit of Rs. 57.79 lakhs for the full FY25. Subsidiary Uniworth Biotech (98.60% held) contributed nil revenue and a marginal loss. The auditor (Khandelwal Ray & Co) issued an unqualified review report, but notes to accounts flag that no provisions have been made for doubtful trade receivables of Rs. 3,010.57 lakhs, other financial assets of Rs. 227.73 lakhs, and interest on borrowings from PNB, IndusInd Bank, and HSBC. The company has not recognized deferred tax assets citing 'consistent losses' and has applied to the RBI for extensions on overdue bills.
Negative for shareholders — the company is loss-making with zero revenue, heavy unprovided doubtful receivables, and unresolved bank borrowings, pointing to serious going concern risks. The stock is likely to remain under pressure and illiquid given the operational dormancy and unresolved legacy issues.